Scientists developed an anti-neuronal drug called Abraxane, which reduced the level of Huntington's proteins in the brain, and a drug that blocks the enzyme that makes the proteins in the brain. However, the effects of these drugs were so effective against the symptoms of Huntington's disease that no effective treatments have been created. In 2007, a small molecule called pembrolizumab was discovered by a team of UCLA scientists that has the potential to be a powerful new treatment for Huntington's.
It is the first drug in the class to be tested as a neuroprotective treatment against the symptoms of the disease. However, the drug has not yet been approved by the Food and Drug Administration for sale in the United States. The FDA has yet to give the drug the green light. CNS Damage Huntington's disease can also be caused by an infection by a microbe, or by the loss of the brain's protective white matter. Both of these causes appear to be caused by a defect in the nerve cells, which is responsible for the transmission of messages between neurons. This can impair communication between neurons as well as between the brain and peripheral organs. The Role of Antibiotics Antibiotics inhibit the action of the enzyme called neurofilament, which is responsible for topiramate topamax and the blood-brain barrier. These drugs also inhibit the formation of neurotoxic free radicals produced by neurons.
Drugs to Prevent and Treat Huntington's Disease Huntington's disease is an inherited disease, and one in which there is no cure. However, medications that can prevent or treat this disease have been developed in research laboratories and clinics. Drugs to control the symptoms of the disease, or to prevent and treat neurological symptoms, are not on the market yet, however. The treatment for Huntington's disease involves the use of anti-neurotransmitters, which are the chemical compounds found in neurons that are normally released by the endocannabinoid system to communicate. These substances are also present in the brain.
The effects of these drugs include decreasing the production of reactive oxygen species, which is a byproduct of the enzyme that creates neurofilament. This topiramate topamax been shown to help improve symptoms in people with Huntington's disease. Anti-oxidants may prevent the breakdown of the brain's protective white matter, which is the first line of defence against neurodegeneration. Until recently little was known about it or exactly how it affected ALS, but recent advances in genetic sequencing technology have allowed scientists to identify a single gene associated with ALS, in an analysis of 1,845 people. The Gene Huntington's disease is an inherited degenerative neurological disease caused by a mutation of the gene for the enzyme responsible for detoxifying oxidative radicals. Although the gene is normally located in the nucleus of the cell and has not been found in any of the cell's other chromosomes, it has been linked with the abnormal accumulation of some toxic and inflammatory molecules called proinflammatory cytokines in the brain. The role of these cytokines is well known, and they can play an important role in the progression of ALS and other neurological diseases, such as multiple sclerosis.